Telescope Innovations Reports Significant Milestones and Financial Results of Fiscal Year 2025

Core Insights - Telescope Innovations Corp. reported revenues of $5.8 million for the fiscal year ended August 31, 2025, an increase from $4.4 million in FY 2024, while experiencing an Adjusted EBITDA loss of $402,000 compared to a loss of $152,000 in the previous year [1][8]. Operational Highlights - The company achieved significant milestones, including continued progress on the Self-Driving Lab (SDL) program with Pfizer and record sales of DirectInject-LC™ [4][8]. - Telescope Innovations successfully produced battery-grade lithium sulfide using a proprietary low-temperature method, with initial samples shipped to battery industry groups in North America and Asia [8]. Financial Highlights - Total expenses for FY 2025 were $7.3 million, up from $5.8 million in FY 2024 [8]. - The company is strategically reinvesting revenues to enhance research and development (R&D) and commercialization capacity, indicating a focus on long-term growth [1][4].